Ⓐ
PeptiBrief
Peptide medicine

Liraglutide

Liraglutide is a clinically used peptide medicine or hormone with established evidence in defined indications.

Formula
C172H265N43O51
Molecular weight
3751.20 g/mol

Evidence confidence

Human
2/5
Some human clinical evidence
1 citation
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
2/5
Partially characterised safety
1 citation

Claimed uses

Mechanisms

Safety notes

Adverse effects, contraindications and monitoring requirements depend on the approved formulation and indication.

Regulation
  • Approved prescription medicine in multiple jurisdictions. Authorised brands and indications differ between diabetes and weight-management products.
  • Prescription or regulated medicine with jurisdiction-specific indications.

References

  1. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management · 2015
Last reviewed
12 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.